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ABSTRACT
The pmrHFIJKLM Operon in Yersinia pseudotuberculosis Enhances
Resistance to CCL28 and Promotes Phagocytic
Engulfment by Neutrophils
Lauren Elizabeth Johnson
Department of Microbiology and Molecular Biology, BYU
Master Science
Yersinia pseudotuberculosis is a foodborne pathogen that is the ancestral strain to
Yersinia pestis, the causative agent of Plague. Y. pseudotuberculosis invades a host through the
intestinal epithelium. The bacteria resist mucosal innate immune defenses including
antimicrobial chemokines and phagocytic cells, and replicate in local lymph nodes. They cause
Tuberculosis-like symptoms, including necrosis of local tissue and granuloma formation. Like all
bacteria, Y. pseudotuberculosis has a net negative charge, which contributes to its susceptibility
to some cationic antimicrobial peptides. Y. pseudotuberculosis is able to reduce this negative
charge by adding 4-amino-4-deoxy-L-arabinose (L-Ara4N) to the lipid A portion of
lipopolysaccharide. The production and addition of the L-Ara4N is coded for by the
pmrHFIJKLM (pmrF) operon. A previous study has shown that the Y. pseudotuberculosis pmrF
operon is important for resistance against polymyxin, but is not important for virulence in mice.
Several previous reports have shown a strong influence of growth temperature on resistance to
antimicrobial peptides and pmrF expression in pathogenic Yersinia species, but these studies also
suggest significant variability between species, and even between strains of individual species. In
particular, the regulation of the Y. pseudotuberculosis pmrF operon and its effect on bacterial
interactions with mucosa-associated antimicrobial chemokines and neutrophils is not understood.
In these studies, we investigated the environmental influences on pmrF expression in Y.
pseudotuberculosis. We found that the promoter activity of the pmrHFIJKLM operon is
increased at lower temperatures (21ºC) and in the presence of human serum. A ΔpmrI mutant
strain of Y. pseudotuberculosis defective for addition of L-Ara4N was found to be more
susceptible to killing by the antimicrobial chemokine CCL28 compared to wild-type. This
suggests that this gene is important in the bacterial defense against antimicrobial chemokines.
However, when the ΔpmrI mutant strain was exposed to human neutrophils, there was a decrease
in phagocytosis as compared to wild-type bacteria. Our results suggest that the regulation of LAra4N modifications in Yersinia is more complex than previously appreciated and varies
between species. Addition of L-Ara4N to Y. pseudotuberculosis appears to enhance resistance to
some antimicrobial peptides like CCL28 and promote greater phagocytic engulfment by
neutrophils. These opposing effects may partly explain why there is no net apparent survival
defect in mutants lacking the pmrF operon during infection.
Keywords: Yersinia pseudotuberculosis, antimicrobial chemokine, phagocytosis, neutrophil,
pathogenesis, immunology
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INTRODUCTION
The immune system
The human immune system consists of an innate and an adaptive immune response to
protect our bodies against foreign invaders. The adaptive immune system is specifically tailored
to adapt to individual pathogens and prevent future infections from the same specific organism.
Conversely, the innate immune system is fast acting and often responds to general groups of
pathogenic organisms. The innate immune system does not “learn” or improve over time. There
are two types of response for the immune system; humoral and cellular. Humoral immunity
includes the complement system, naturally occurring antibodies, and other soluble antimicrobial
proteins [1]. These humoral immunity soluble proteins may be constantly circulating in the blood
or are produced by cells in response to invading microorganisms. The cellular response of the
innate immune system includes activation of phagocytic white blood cells. These include
macrophages, granulocytes, and dendritic cells. The granulocytes are a subset of white blood
cells that have multi-lobed nuclei and contain granules. Neutrophils, basophils, eosinophils, and
mast cells make up this group. Basophils, eosinophils, and mast cells can initiate inflammatory
pathways that result in allergies and asthma [2], however eosinophils are important for protection
against parasitic infections [3, 4]. Neutrophils are the most abundant white blood cell and one of
the initial responders during inflammation [5].
Neutrophils
Neutrophils remain inactive in the blood until external stimuli activate them to begin
clearing an infection. When activated, neutrophils can aid in clearing an infection through
phagocytosis, degranulation, and expelling Neutrophil Extracellular Traps (NETs). Phagocytosis
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is the most common activity of neutrophils, and results in a target bacterium being engulfed it
into a phagosome. Once the bacterium is in the neutrophil, granules bind to the phagosome and
release large amounts of antimicrobial peptides and producing free radicals, resulting in death of
the bacteria [5, 6]. Degranulation can also result in extracellular release of granules, which can
cause tissue damage, but also results in death of extracellular invaders [6]. The last mechanism is
the release of NETs. Neutrophils can release a network of granule proteins and chromatin that
form a fibrous matrix that can trap and kill bacteria [7]. This can be activated in the presence of
lipopolysaccharide or other soluble factors, such as interleukin-8 (IL-8) [7].
While neutrophils can be activated by cytokines produced by other immune cells, the
most potent way to activate neutrophils is by direct contact with a pathogen. Neutrophils are able
to detect bacteria and other microorganisms by the use of toll-like receptors (TLRs). TLRs are
pattern recognition receptors, and can detect microbial associated molecular patterns (MAMPs).
Neutrophils express all but one of the ten TLRs, majority of which are found on the cell surface
[8, 9]. They can be used to detect gram-positive and gram-negative bacteria, viruses, and fungi.
Several of the TLRs are used to detect bacteria specifically. TLR2 can act together with TLR1 or
TLR6 to detect di-acylated or tri-acylated peptides on gram-positive bacteria. TLR4 is able to
detect the lipid A of LPS on gram-negative bacteria [10]. Neutrophils can also detect bacteria via
TLR5 which can detect bacterial flagellin [11]. Upon TLR activation, a neutrophil can then
produce pro-inflammatory cytokines, increase free-radicals, and initiate phagocytosis [9].
Another way that neutrophils can detect infection is through complement receptors on the
cell surface. Complement proteins are soluble in the blood and work as a signaling cascade to
initiate inflammation, opsonization, and pore formation in a cell surface. When the complement
cascade is active, complement proteins C3a, C4a, and C5a participate in inflammation, C5b can
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form a membrane attack complex leading to pore formation and cell death, while C3b
participates in opsonization. Opsonization occurs when complement proteins coat a cell surface,
marking it for phagocytosis [12]. Neutrophils have complement receptors C1qR, CR1, CR3,
CR4, and C5aR on their surface. When the CR1 receptor binds to C3b, the neutrophils can more
easily phagocytize the cell that the complement is bound to [13, 14].
Chemokines
Innate immune cells, including neutrophils, need chemokines to migrate to the location
they are needed. Chemokines are low molecular weight signaling proteins used in chemotaxis.
There are four subfamilies of chemokines, CXC, CC, CX3C and XC, organized by the spacing
of their first cysteine residues [15]. Chemokines can be present to direct regular cell movement,
and can recruit immune cells to a sight of infection [15]. Homeostatically expressed chemokines
are produced by the thymus and lymphoid tissue for regular cell migration, however a wide
range of cells produce specific chemokines after infection occurs [16].
Immune cells need chemokine receptors to be able to recognize and interact with a
chemokine. Chemokine receptors are commonly found on hematopoietic cells, and offer
redundancy where multiple chemokines may bind to one receptor, and one chemokine may bind
to multiple receptors. Chemokine receptors are G protein-coupled receptors that have seven
trans-membrane domains [17, 18]. Hematopoietic cells have several different responses to
binding to a chemokine, which can include chemotaxis, cytotoxic response, or others [15-18].
Immune cells follow a chemokine gradient and go the direction of higher concentration,
migrating to the location of chemokine origination and infection.
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Antimicrobial peptides
Cationic antimicrobial peptides (AMPs) are an important part of the innate immune
system due to their ability to directly kill pathogens. These short proteins have been shown to use
electrostatic interactions to bind to negatively charged phosphate groups on bacterial surfaces.
Once bound, the peptide can then form pores in the bacterial cell, resulting in ion channels and
cell death [19]. AMPs can be used as broad-spectrum antimicrobials and have shown to be
effective against bacteria, enveloped viruses, and fungi.
There are two major categories of cationic AMPs; cathelicidins and defensins. The
cathelicidins are named for their conserved cathelin regions. Only one cathelicidin, LL-37, is
found in humans and is produced in epithelial cells and leukocytes [19-22]. Cathelicidins contain
α-helical structures, while the defensins are made up of anti-parallel β-sheets. The defensins are
sub-categorized into two groups; the α-defensins and β-defensins. The α-defensins are typically
found in neutrophils and NK cells. The β-defensins are more wide-spread and can be found in a
wide variety of leukocytes and epithelial cells [23]. Defensins have a positively charged domain
as well as a hydrophobic domain that allow them to penetrate the negatively charged bacterial
membrane and cause pores, leading to death [21, 24]. The hydrophobic domain can be important
for stabilizing the peptide on the target cell [23, 24]. The ability of defensins to form pores in a
cell surface has been shown by visualizing with electron microscopy electron-dense deposits on
the cell surface where pores have formed [25].
Killing mechanism
There have been three proposed methods for AMP pore formation; barrel-stave, carpet,
and toroidal-pore. The barrel-stave method requires multiple peptides to penetrate the cell
4

surface, with the hydrophobic region facing out. When multiple peptides have formed a ring in
the membrane, the pore is formed resulting in cell death [26]. The carpet method proposes that
the AMPs align parallel to the membrane, creating a “carpet” covering the cell with the
hydrophobic regions contacting the lipid bilayer. As the coating is made, sections of the peptide
coated membrane become separated and a pore is formed [26]. The toroidal-pore method acts
similarly to the barrel-stave method due to multiple peptides forming a ring in the cell
membrane. However, in the toroidal-pore method, the AMPs are causing the lipid monolayers to
bend continuously through the membrane until bound with the opposite lipid monolayer, forming
a pore of AMPs and hydrophilic lipid heads [26]. It has also been proposed that AMPs could
affect bacteria through inhibiting enzymatic activity or synthesis of key cellular elements such as
the cell wall, nucleic acid, proteins, or the cytoplasmic membrane [27].
Antimicrobial chemokines
Several chemokines have been found to have a novel function as an antimicrobial
peptide. The antimicrobial chemokines are cationic and similar in structure to defensins [28].
However, not all cationic chemokines have antimicrobial properties [28]. Different chemokines
appear to require different regions of their structure to act as an antimicrobial, which may mean
that different antimicrobial chemokines have different killing methods. It has been found in
CXCL6 that the N-terminal domain has more antimicrobial properties than the C-terminal
domain [29]. Conversely, in CCL28 and CXCL9 it has been seen that the C-terminal domain is
necessary for antimicrobial properties, and the N-terminal domain does not have any
antimicrobial activity on its own [30, 31]. Multiple studies have shown membrane disruption as a
killing mechanism of antimicrobial chemokines through electron microscopy [29], as well as
flow cytometric assays with propidium iodide entrance into the cell [32]. These antimicrobial
5

chemokines have shown to be effective against gram-positive and gram-negative bacteria, fungi,
and parasites [16, 30, 32].
CCL28
The chemokine CCL28, previously referred to as mucosae-associated epithelial
chemokine (MEC), is found in mucosal tissues, including lungs, intestines, mammary glands,
and nasal passages [33]. The chemokine binds to chemokine receptors CCR3 and CCR10. While
most chemokines have 4 cysteine residues, CCL28 has 6. It is responsible for recruiting IgAproducing plasma cells, eosinophils, and activated T lymphocytes to these mucosal tissues [16,
34]
CCL28 has recently been shown to have direct antimicrobial activity [34]. It has been
shown that there is a positively charged C-terminus that is required for CCL28 mediated
bacterial killing [30]. The structure of this chemokine is highly similar to the structure of βdefensins and so it is believed that they have a similar killing mechanism [21]. The positively
charged C-terminus alone is not sufficient to cause cell death, however it is unknown what else is
required [30]. While CCL28 can kill bacteria in low-osmolarity conditions in vitro, in higher
osmolarity solutions the peptide can bind to the surface of bacteria without causing death. The
impact of such binding on bacterial interaction with host tissues or immune cells is unknown but
deserves further investigation.
Lipopolysaccharide
Gram-negative bacteria have an inner membrane, with a thin peptidoglycan cell wall, and
an outer membrane [35]. The outer leaflet of the outer membrane contains lipopolysaccharide
(LPS). LPS consists of three sections; the lipid A, the core oligosaccharide, and the O-antigen.
6

Even though LPS is highly conserved, there is variability between the exact structure of the LPS
between different bacterial strains [36]. Lipid A consists of an acylated glucosamine disaccharide
with flanking phosphate groups and fatty acid chains that anchor the LPS to the bacterial
membrane. The negatively charged phosphate groups can aid in dipole interactions with other
LPS molecules. LPS is beneficial to bacteria by adding to physical rigidity, as well as decreasing
permeability to prevent entrance of antimicrobial compounds [37]. LPS is highly
immunostimulatory, immune cells can produce very potent pro-inflammatory cytokines such as
TNF-α and IL-1β when even small amounts of lipid A are detected [38-40].
Yersinia pseudotuberculosis
Yersinia pseudotuberculosis is a gram-negative pathogenic bacterium that is ancestral to
Yersinia pestis, the causative agent of bubonic and pneumonic plague [41, 42]. Y.
pseudotuberculosis is less virulent than Y. pestis and causes Tuberculosis-like symptoms such as
granuloma formation and local necrosis, as well as gastroenteritis and lymphadenitis with
possible complications of reactive arthritis and erythema nodosum [41, 43, 44]. Even though Y.
pseudotuberculosis and Y. pestis are so closely related, the infection methods between these two
bacteria are very different. While Y. pestis can infect hosts by fleas and aerosols, infection by Y.
pseudotuberculosis typically occurs through contaminated food and water. Y. pseudotuberculosis
invade the intestinal epithelium through M cells into Peyer’s patches or directly through the
epithelial layer. They can colonize Peyer’s patches within hours of infection or they can be
engulfed by macrophages, where they can survive intracellularly, and taken to the lymph nodes
to colonize. Pathogenic Yersinia species have a plasmid (pYV in Y. pseudotuberculosis and
pCD1 in Y. pestis) that codes for necessary virulence factors, including a type III secretion
system (TTSS) [44-47]. This TTSS is required for survival and replication in the host’s lymphoid
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tissue [46]. Through the TTSS Yersinia can secrete virulence factors known as Yersinia outer
proteins (Yops) into a target host cell. Some Yops have been shown to induce apoptosis in
phagocytic cells [45, 46].
While Yersinia can induce apoptosis in macrophages and dendritic cells, neutrophils are
resistant to pYV+ Yersinia induced apoptosis [48, 49]. Phagocytosis of the bacteria is increased
in pYV-deficient Yersinia; however neutrophil cell death occurs in higher levels due to reactive
oxygen species production by neutrophils in response to phagocytosis of the bacteria [49]. It has
also been shown that Y. pseudotuberculosis and Y. pestis are resistant to killing by neutrophils
through use of the Yops [44, 47, 50]. In Y. pestis it has been shown that the PhoP-PhoQ two
component system is important for neutrophil intracellular survival of the bacteria [48].
Although Yersinia devote considerable resources to surviving against neutrophil attack, they are
critically important in early defenses against Y. pestis lung infections. Y. pestis that produce YopJ
are able to suppress mouse neutrophil chemotaxis during the first 24 hours after infection.
However, when neutrophils are induced to migrate to the lung prior to infection the numbers of
bacteria are significantly decreased and mouse survival is enhanced [51]. However, a separate
study found that Y. pestis was equally virulent in mice with or without neutrophils [52]. The
interactions between Yersinia and neutrophils are important to study and understand since
neutrophils are such a critical part of the innate defense system.
LPS modifications
Many pathogenic bacteria have defense mechanisms that can be used to evade a host’s
immune system during an infection. Since the LPS is so immunostimulatory due to the lipid A,
many gram-negative bacteria have specific mechanisms to conceal LPS from being detected. For
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example, Yersinia are able to alter their fatty acid chain composition when grown at various
temperatures. When grown at 21ºC, Y. pestis, Y. pseudotuberculosis, and Y. enterocolitica all
produce hexa-acylated fatty acid chains on the lipid A. All three strains convert to a tetraacylated lipid A when they are grown at 37ºC (Fig. 1) [53]. Having greater hexa-acylation
patterns can aid in lower cell permeability and greater protection from antimicrobials that may
cross the membrane. The bacteria benefit in mammalian infection with a tetra-acylation because
it is less immunostimulatory. When monocytes are presented with the hexa-acylated lipid A, they
respond by producing proinflammatory cytokine TNF-α. The same response was not observed
when the tetra-acylated lipid A was used [53]. In addition to showing how bacteria can make
physical alterations to be more clandestine, it shows that sometimes bacteria sacrifice some
aspects of their physical fitness (in this instance, sacrificing membrane defenses) to increase
probability of survival in a host.
The innate immune system frequently detects gram-negative bacteria due to the net
negative-charge caused by the negatively charged phosphate groups on the lipid A structure. This
negative charge facilitates cell recognition by cationic antimicrobial peptides, ultimately causing
death to the bacteria by pore formation in the membrane [19]. Many gram-negative bacteria have
the ability to modify the lipid A structure to conceal the negative charges that are present,
resulting in decreased detection by cationic AMPs [40]. One mechanism used to accomplish this
is the addition of phosphoethanolamine [54-56]. This addition causes a slightly less negative
charge of the outer bacterial membrane by addition of phosphoethanolamine to either the lipid A
or the core oligosaccharide. It has been shown that this mechanism does happen in Yersinia, and
can be increased in low temperatures in Y. pestis [57]. Another defense mechanism is the
addition of a positively charged amino sugar 4-amino-4-deoxy-L-arabinose (L-Ara4N) to the
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lipid A structure at the negatively charged phosphate groups (Fig.1). This occurs in E. coli,
Salmonella, Yersinia, and other gram-negative bacteria [56, 58]. This mechanism is carried out
through the pmrHFIJKLM (pmrF) operon (Fig. 2a), sometimes referred to as the arn operon [5961].
L-Ara4N modification carried out by the pmrHFIJKLM operon
The process of L-Ara4N production and addition is started when Ugd (encoded by the
pmrE gene, which is not part of the pmrF operon) converts UDP-glucose to UDP-GlcUA [62].
The pmrI gene, sometimes referred to as arnA, is responsible for a large portion of the creation
and addition of L-Ara4N to the bacterial surface (Fig. 2b). The PmrI protein has two domains
that are necessary for L-Ara4N addition (Fig. 2b) [63], an N-terminal formyltransferase and a Cterminal decarboxylase. The C-terminus catalyzes the change of UDP-GlcUA to UDP-Ara4O
[64]. PmrH then facilitates the change to UDP-L-Ara4N [65]. The N-terminal formyltransferase
domain of PmrI transfers a formyl group to the UDP-L-Ara4N [64]. PmrF then transfers this
molecule to the inner membrane by removing UDP and attaching the molecule to undecaprenyl
phosphate in the inner membrane [65, 66]. PmrJ then removes the formyl group and the
molecule is transferred to the outer membrane [67]. While it is still unknown exactly which
proteins are responsible for the transport of the molecule to the outer membrane, it has been
shown that PmrL and PmrM may play a role in this [68]. However, loss of the pmrL and pmrM
genes does not prevent L-Ara4N addition, and there is evidence that these genes can be
supplemented if function is lost [69]. Finally, PmrK transfers L-Ara4N to the lipid A structure in
a well-characterized reaction [70, 71].
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In Y. pestis it has been shown that in the absence of arnB (pmrH) there is a compensatory
gene, wecE, which partially makes up for the loss of the gene [72]. L-Ara4N was still added to
the Lipid A in lower levels even after deletion of the arnB gene. The wecE gene is known for its
role in biosynthesis of enterobacterial common antigen (ECA). ECA is found on all members of
the Enterobacteriaceae family of bacteria. ECA is found on the outer leaflet of the outer
membrane, similar to LPS. ECA is partially composed of an aminosugar heteropolymer [73]. LAra4N is also an aminosugar so it is reasonable that a gene helping the production of ECA could
also help the production of L-Ara4N. After the loss of wecE and arnB, the L-Ara4N was no
longer added [72]. This results in maintaining a higher level of resistance to cationic
antimicrobial peptides even if there are conditions that prevent the original L-Ara4N addition
mechanism to be functional. Specifically, the wecE gene codes for TDP-4-oxo-6-deoxy-Dglucose transaminase. There is a gene in Y. pseudotuberculosis, rffA, that is assumed codes for
the same product, based on 99.73% gene homology [74]. There have been no studies on this
gene, however if the assumption is correct that this gene is the same as wecE, then the rffA gene
may be able to aid in the addition of L-Ara4N in Y. pseudotuberculosis as well.
The impact of L-Ara4N lipid A modification on bacterial fitness in host environments is
not straightforward. While in S. typhimurium it has been shown that loss of the pmrF operon
results in decreased virulence of the bacteria during infection [75], in Y. pseudotuberculosis a
loss in pmrF function does not affect virulence in mice when infected by either intravenous or
via gastric inoculation [60]. However, L-Ara4N has been implicated in the ability of Y. pestis to
survive in fleas [71]. Interestingly, recent evidence also suggests that L-Ara4N modification may
be detrimental to bacteria in some instances. Researchers investigating Burkholderia infection in
Cystic Fibrosis patients were able to synthesize L-Ara4N modified and unmodified Burkholderia
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lipid A. Their study showed that when the lipid A was modified with L-Ara4N, HEK cells were
stimulated to produce NF-κB and macrophages were stimulated to produce IL-8, which would
result in increased inflammation. Neither of these responses occurred when the lipid A was not
modified [76]. Others have shown that Burkholderia penta-acylated lipid A is still highly
immunostimulatory compared to hexa-acylated lipid A due to the L-Ara4N residues on the lipid
A [77]. It’s possible that the positive charges of the L-Ara4N are responsible for activating parts
of the TLR4-MD2 complex, resulting in activated immune cells. These studies suggest that LAra4N modified lipid A may be a detriment to bacteria trying to evade detection by the immune
system.
Regulation of the pmrF operon
In Salmonella and Y. pestis, the pmrF operon is regulated by the PmrA-PmrB and the
PhoP-PhoQ two-component systems [60, 61, 78, 79]. These systems have been best studied in
Salmonella enterica serovar typhimurium in response to high iron and/or low magnesium levels.
In this Salmonella strain, PmrB is the sensor kinase that is activated by high Fe3+ levels, which in
turn activates the regulatory protein PmrA to directly control pmrF expression [60]. It has also
been shown that PmrA activation occurs in low Mg2+ concentrations when the PhoP-PhoQ
system is activated. This leads to an increase in production of PmrD, which activates PmrA at a
post-transcriptional level [60] (Fig. 3A). High levels of Fe3+ also reduce PmrD transcription [80]
thus reducing the input from the PhoP/Q system. Y. pestis does not have PmrD, but can still use
both two-component systems to regulate pmrF expression (Fig. 3B) [48]. Y. pseudotuberculosis
also lacks PmrD, and unlike in Y. pestis, pmrF expression is independent of PmrA-PmrB (Fig.
3C) despite a conserved PmrA binding site [60, 61]. Polymyxin resistance has been shown to
increase in Y. pseudotuberculosis in low Fe3+ levels [60], and a second LysR-type regulator for
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the pmrF operon was identified [69]. This second regulator is not present in Y. pestis and is
significantly different in Y. enterocolitica.
These discrepancies among the ways closely related Yersinia regulate the pmrF operon
are interesting and suggest a need for clarification of the exact factors that control pmrF
expression and polymyxin resistance. The influence of temperature has been especially difficult
to establish. For instance, Y. pestis strain KIM resistance to polymyxin was found to be
unchanged at various temperatures [81], while another group found Y. pestis strain KIM6+
resistance to polymyxin is increased at 21ºC compared to 37ºC [53]. Y. enterocolitica is more
susceptible to polymyxin than either Y. pestis or Y. pseudotuberculosis under every condition
[53, 81]. However, non-pathogenic Y. enterocolitica strain PR serotype O:1,6 resistance to
polymyxin is decreased at 37ºC [81] as is L-Ara4N modification in Y. enterocolitica strain 8081
[79]. Conversely, most previous studies have shown that Y. pseudotuberculosis resistance to
polymyxin is decreased at temperatures lower than 37ºC (21ºC, 26ºC) [53, 81], even though Y.
pseudotuberculosis strain WS 66/89 serogroup III exhibited diminished resistance at 37ºC [81].
One report suggested that pmrF transcript levels in Y. pseudotuberculosis were nonexistent at
temperatures below 37ºC [60], however L-Ara4N addition has been measured at higher and
lower temperatures in both Y. pseudotuberculosis and Y. pestis [53]. The exact mechanisms
contributing to polymyxin resistance need to be clarified due to such high diversity between
Yersinia species and strains. Further, the differences that are seen in pmrF expression patterns
suggest that pmrF regulation is more complex than one would assume. Even significant
differences are seen between strains of Yersinia that are very closely related. This highlights the
need for further study of more isolates so that L-Ara4N regulation can be better understood.
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EXPERIMENTAL APPROACH
Due to the dramatic differences in polymyxin resistance between Y. pseudotuberculosis
and the other Yersinia species, the exact conditions of pmrF regulation need to be studied in
greater detail. We determined to do this by focusing on three objectives.
The first objective of this study was to characterize the expression of the pmrF operon in
Y. pseudotuberculosis IP32953 under various environmental conditions. To do this, we cloned
the pmrF promoter in front of a promoterless green fluorescent protein (GFP) gene to create a
reporter plasmid. We then used flow cytometry to measure expression changes in response to
various external factors. We wanted to test different environmental conditions that the bacteria
may encounter before and during an infection, so expression was measured in rich and minimal
media, high (37ºC) and low (21ºC) temperatures, and in the presence of human serum and
antimicrobial chemokine CCL28. We predicted that expression of the operon would increase at
37ºC, as well as in the presence of human serum and CCL28 since the bacteria might benefit
from the added protective measures of L-Ara4N addition under these conditions.
The second objective of this study was to measure the effect that the pmrI gene (required
for L-Ara4N addition) has on bacterial resistance to antimicrobial chemokine CCL28. In order
for Y. pseudotuberculosis to establish a successful infection, they must cross through the mucosal
layer of the intestinal epithelium. This means they need to be able to avoid host defense peptides,
including antimicrobial chemokines, and phagocytic cells. We wanted to see the importance of
L-ara4N addition in the bacterial resistance of these various conditions. Since the pmrI gene is
responsible for multiple steps in the production of L-ara4N [63], it seemed a clear target to
knock-out in an attempt to remove L-ara4N addition to the bacteria. Since CCL28 is produced in
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mucosal surfaces, it is reasonable to assume that this is one antimicrobial chemokine that Y.
pseudotuberculosis would encounter during an infection. This first required the creation of a
ΔpmrI mutant and complemented mutant in the Y. pseudotuberculosis IP32953 background.
Using the ΔpmrI and wild-type strains of Y. pseudotuberculsosis, we then used flow cytometry to
detect levels of CCL28 binding to bacteria, as well as bacterial susceptibility to killing by the
peptide. We hypothesized that the cationic CCL28 would be repelled by the positively charged
L-Ara4N, resulting in the ΔpmrI mutant showing higher binding and reduced survival compared
to the wild-type strain.
The third objective of these studies was to intended to help us better understand the
impact that the L-Ara4N addition and CCL28 binding may have on the outcome of interactions
with human neutrophils. Since neutrophils are the most common white blood cell and are very
important first responders to bacterial infection, we decided to use them as a model for observing
the effects of L-Ara4N addition on phagocytosis. In addition, the consequences of CCL28
binding to the surface of a bacterium have not been studied. Pathogens binding to host proteins
often result in different consequences. For example, when a bacterium is coated in the
complement protein they are marked for phagocytosis by immune cells [12, 13]. However, there
are some pathogens that can coat themselves in human proteins to avoid detection by the
immune system [82, 83]. We wanted to see if CCL28 binding to the surface of Y.
pseudotuberculosis would result in either of these effects. We developed a phagocytosis assay in
which GFP expressing strains of Y. pseudotuberculosis were used to measure the proportion of
neutrophils that are able to phagocytose bacteria under different conditions. We compared the
efficiency of the neutrophils to engulf wild-type, ΔpmrI mutant, and ΔpmrI mutant
complemented strains using flow cytometry. We also measured the effect of CCL28 binding to
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the bacterial surface had on neutrophil phagocytosis. We hypothesized that a lack of L-Ara4N on
the surface of the ΔpmrI mutant, would increase the ability of neutrophils to phagocytose
bacteria. We also hypothesized that CCL28 bound bacteria would increase phagocytosis, acting
as an opsonin.
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MATERIALS AND METHODS
Bacterial strains and growth conditions
Yersinia pseudotuberculosis IP32953, a virulent clinical isolate, was used in these studies. The Y.
pseudotuberculosis hldD::Tn5 mutant was made previously in a non-virulent Y.
pseudotuberculosis via random transposon mutagenesis and identified as having a truncated LPS
down to the heptose group in the core region [84, 85]. The hldD::Tn5 mutant contains
kanamycin resistance. GFP fluorescent versions of wild-type (wt) Y. pseudotuberculosis, Y.
pseudotuberculosis ΔpmrI, and Y. pseudotuberculosis ΔpmrI + pACYCpmrI (see below) were
created by electroporating pAKgfp1 plasmid (Addgene plasmid # 14076) into each strain [86].
The MFDpir strain of E. coli has been previously infected with Mu bacteriophage, contains
genes that allow replication of Mu-dependent suicide plasmids, and requires diaminopimelic acid
(DAP) addition to media to replicate [87]. Overnight cultures were inoculated in 3mL Terrific
Broth (TB) (Gentrox, Worcester, MA) shaking at 37°C unless otherwise stated. Antibiotics were
added when appropriate; chloramphenicol (10μg/mL), ampicillin (100 μg/mL), and kanamycin
(30μg/mL).
Electroporation
Electrocompetent cells were made by growing 5mL of the strain overnight, pelleting the cells
into 4 microcentrifuge tubes, and washing the cells four times in molecular grade water on ice.
The electroporation took place in a 1mm cuvette on setting EC1. The transformed cells were
immediately suspended in 800µL of Recovery Media (Lucigen) and shaken at the appropriate
temperature for 1-2 hours before plated.
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Mutant Generation
The ΔpmrI mutant of Y. pseudotuberculosis was created using a technique previously described
[88]. Briefly, by amplifying the upstream region and downstream region (with 20bp out of gene
either side and 40 bp within the gene) of the pmrI gene using primers that would create products
with areas of homology with each other. The primers used were the pmrI upstream F, pmrI
upstream R, pmrI downstream F, and pmrI downstream R (Table 1). Once the two pieces were
amplified, 1μL of each product was combined together with 8μL of taq polymerase and 10μL of
molecular grade water. To “stitch” the upstream and downstream regions together, a PCR was
run with the following conditions: 98°C for 1 minute and 30 seconds, then 15 cycles of 98°C for
15 seconds, 55°C for 20 seconds, and 72°C for 1 minute and 30 seconds. Then 1μL of this new
product is used as a template for a new PCR reaction using 2 nested primers, one of which is
upstream of the gene and one downstream, pmrI nested F and pmrI nested R (Table 1). The
resulting product, as well as suicide plasmid pRE112 (Addgene plasmid # 43828) was digested
with XbaI and SacI and then ligated together. The pRE112 plasmid contains a SacB gene for
sucrose sensitivity [89]. This new plasmid was then heat shocked into chemically competent
MFDpir and the cells were grown on Luria Broth (LB) plates that had be supplemented with
chloramphenicol and diaminopimelic acid (DAP). MFDpir cells require the addition of DAP to
grow. Once the MFDpir cells with the plasmid were grown up, they were mated with Y.
pseudotuberculosis by combining 500µL of each culture and pelleting the cells together,
resuspending them in 30µL TB and spotting them on a TB + DAP plate for 24 hours. The cells
were then collected and grown overnight in TB with chloramphenicol. The resulting Y.
pseudotuberculosis cells contained single crossover event with the plasmid, since the plasmid
cannot replicate in Y. pseudotuberculosis without crossing over. Cells were then grown in
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antibiotic free media to allow a double-crossover event to take place. The cells were then plated
on TB + sucrose plates and a colony PCR was performed to check the length of the pmrI gene,
using the pmrI upstream F and pmrI downstream R primers, several colonies were positive for
deleted pmrI gene.
Chemokine Preparation
Lyophilized human CCL28 and CCL20 were purchased from PeproTech, Rockyhill, NJ and
prepared by diluting each vial of 100μg into 2mL of filtered PBS containing 0.1% BSA. The
mixture was left at room temperature to allow the chemokine to properly dissolve. The
chemokine was then put into single dose aliquots of 12μL to avoid multiple freeze/ thaw cycles.
The final concentration of the chemokine preparation was 0.5μg/10μL.
pmrHFIJKLM Reporter Strain Generation
The pmrF operon promoter was amplified using the “pmrH pro F” and “pmrH pro R” primers
(Table 1), resulting in the addition of XbaI and HindIII restriction sites to the 5’ and 3’ end
respectively. The product was then digested with XbaI and HindIII restriction enzymes. The gfp
gene was amplified from the pAKgfp plasmid using the gfp F HindIII and gfp R SalI primers
(Table 1), resulting in the addition of HindIII and SalI restriction sites to the 5’ and 3’ end
respectively. The gfp gene product was then digested with HindIII and SalI restriction enzymes.
The digested promoter and gfp products were then ligated together. The pACYC184 plasmid
(GenBank Accession #: X06403) was digested with XbaI and SalI restriction enzymes. This
plasmid contains a chloramphenicol resistance gene [90]. The pmrF promoter-gfp construct was
then ligated into the digested pACYC184. The plasmid was then heat shocked into chemically
competent E. coli (Lucigen, Middleton, WI). Once the E. coli were grown overnight, the plasmid
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was isolated using the QIAprep Spin Miniprep Kit (QIAGEN, Valencia, CA). The plasmid was
then electroporated into electrocompetent wild-type Y. pseudotuberculosis and grown overnight
in TB media with chloramphenicol. A colony PCR was then performed to confirm plasmid
presence.
pmrF Expression Assay
The pmrF expression reporter strain of Y. pseudotuberculosis was grown overnight at 30ºC in
M9 and TB media. The bacteria were subcultured by adding 50µL of culture to 1mL of TB or
M9 with a negative control and the appropriate test condition; either 10% human serum or 0.4nM
CCL28 or CCL20. After 6 hours of incubation the samples were run on the flow cytometer to
detect GFP levels. Flow cytometry data was obtained using a BD Accuri C6 Flow Cytometer and
analyzed using the BD Accuri software. The mean fluorescence was compared between the
varying conditions to determine gene expression.
Growth Rate in Polymyxin
After the wild-type, ΔpmrI, and ΔpmrI complemented strains of Y. pseudotuberculosis were
grown overnight, each strain was diluted to an OD600 of 1.0 +/- 0.1. The cultures were then
centrifuged and resuspended in 1mL of PBS. In triplicate, 20µL of bacteria and 10µL of BSA
were added to individual microcentrifuge tubes and incubated at 37ºC for 30 minutes. A 96 well
plate was prepared with an LB/ rezasurin/ polymyxin mixture at 0.135mg/mL concentration
rezasurin. 50µL of this initial mixture was added to columns 1,2, and 4-12 of the 96 well plate.
Polymyxin was added to the wells in column 3 in LB at a concentration of 100µg/mL and 1:2
dilutions of polymyxin were created across the plate. The highest level of polymyxin is
100µg/mL and the dilutions continue until 0.2µg/mL. Column 1 and 2 have 50µL of PBS added.
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After the 30 minute bacteria incubation is complete, the cells are washed and resuspended in
2mL of PBS. 50µL of this culture is then added to columns 2-12. The plate is then read on a
plate reader measuring rezasurin fluorescence to obtain a time 0 reading and then incubated at
37ºC for the duration of the experiment, with plate readings being taken every 30 minutes.
Resazurin becomes fluorescent when metabolized by the bacteria, this allows resazurin to be
used to achieve a very accurate minimum inhibitory concentration.
Chemokine Binding Assay
After the wild-type, ΔpmrI, and ΔpmrI complemented strains of Y. pseudotuberculosis were
grown overnight, each strain was subcultured and grown for approximately 2 hours, until the
OD600 read 0.6. 1mL of each culture was then centrifuged and resuspended in 100μL 0.01%
BSA in PBS (PBSA). In triplicate, 5µL of culture was added with 100uL BSA and either 10μL
0.1% BSA in PBS or 10μL of CCL28 with a final concentration of 0.5μg/15μL. The samples
were then incubated on ice for 30-60 minutes. The samples were all then centrifuged and washed
three times with PBSA. Then 10μL of streptavidin-labeled anti-CCL28 antibody (R&D Systems)
was added to each tube for 30 minutes to allow the antibody to bind. They were then washed in
PBSA, and 5μL fluorescent APC (which binds to streptavidin) (BD Biosciences) is added to
1mL PBSA and then 100μL of this was added to each sample. The samples incubated for another
hour, when they were then washed in PBSA again. The samples were then run on a flow
cytometer to see how many of the bacterial cells were APC positive, meaning the cells had
bound CCL28. Flow cytometry data was obtained using a BD Accuri C6 Flow Cytometer and
analyzed using the BD Accuri software.
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Chemokine Killing Assay
After the wild-type, ΔpmrI, ΔpmrI complemented strain, and hldD::Tn5 strains of Y.
pseudotuberculosis were grown overnight, each strain was subcultured by adding 50μL
overnight culture to 2mL TB and grown for approximately 2 hours, until the OD600 read 0.6.
Then 1mL of each culture was centrifuged and resuspended in 1mL of 1mM potassium
phosphate buffer (PPB) (a low osmolarity buffer). 40μL of each culture was added to 1mL of
1mM PPB to dilute. From this, in triplicate, 100uL of culture was added individual
microcentrifuge tubes. Either 10μL of 0.1% BSA or 10μL of CCL28 was added for a final
concentration of 0.5μg/100uL. The tubes were then vortexed thoroughly and incubated at 37°C
for 90 minutes. After the incubation, 200μL of dilute 1μm polystyrene beads (1:62500)
(Polybead ® Polystyrene 1µm Microspheres, Polysciences Inc., Warrington, Pennsylvania) were
added to each sample, followed by 7μL of propidium iodide (PI) (Invitrogen, Carlsbad,
California) and vortexed. Flow cytometry was used to count to 30,000 beads and numbers of
viable cells were compared to bead count. Flow cytometry data was obtained using a BD Accuri
C6 Flow Cytometer and analyzed using the BD Accuri software. The percent survival is then
calculated with the following equation (Treated (bacteria total-PI+)) / (Untreated (bacteria totalPI+)) x100.
Neutrophil Isolation
Human neutrophils were isolated from whole human blood using a density gradient according to
a protocol previously outlined [91]. Briefly, 5mL whole human blood obtained from volunteer
donors was layered onto 5mL of Lympholyte Poly (Cedarlane Laboratories, Burlington, Ontario)
and centrifuged at room temperature for 35 minutes. The polymorphonuclear cell layer was
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removed and treated with red blood cell lysis buffer multiple times until there were no red blood
cells visible. The cells were then washed in Hanks Balanced Salt Solution and are counted using
a hemocytometer.
Phagocytosis Assay
After the GFP wild-type, GFP ΔpmrI, and GFP ΔpmrI complemented strains of Y.
pseudotuberculosis were grown overnight with ampicillin, each culture was diluted to an OD600
of 1+/- 0.1 and then resuspended in Hanks’ Balanced Salt Solution (HBSS)(Gibco by Life
Technologies). In triplicate, 1,000,000 bacteria from each culture were added to individual
microcentrifuge tubes containing 90μL HBSS. Each tube either had 10uL of human serum
(obtained from a volunteer donor), BSA, or CCL28 added. All of the tubes were then vortexed
and incubated at 37°C for 30 minutes. The bacteria were then washed in HBSS and 100,000
human neutrophils were added to each tube in a volume of 200uL. These samples were then
incubated at 37°C for 30 minutes. The samples were then put on ice and run on the flow
cytometer. Flow cytometry data was obtained using a BD Accuri C6 Flow Cytometer and
analyzed using the BD Accuri software. The flow cytometer counted to 10,000 neutrophils by
gating around the appropriate population and the percent of neutrophils that were positive for
GFP were observed.
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RESULTS
Expression of pmrHFIJKLM operon increases at 21ºC, in rich growth media, and in human
serum
It is known that in Yersinia pestis and Yersinia enterocolitica the susceptibility to
polymyxin is much greater at 37ºC than at lower temperatures [53, 79], and Y. enterocolitica has
been shown to have decreased pmrF expression at 37ºC [79]. Interestingly, Y.
pseudotuberculosis PB1 strain has shown to follow the opposite trend, in that susceptibility to
polymyxin is greater at 21ºC [53]. The effect of temperature on expression of the pmrF operon
has not been reported in Y. pseudotuberculosis strain IP32953. We wanted to determine whether
the expression of the pmrF operon in Y. pseudotuberculosis IP32953 follows the same trend that
has been seen in Y. pseudotuberculosis strain PB1 and Y. pestis, or if it would resemble Y.
enterocolitica. A reporter plasmid carrying the pmrF promoter (including the PhoP binding site)
fused to GFP was created. We tested the effect of growth temperature, both in rich growth media
Terrific Broth (TB) and minimal media M9, on pmrF promoter activity. After the bacteria were
grown in their respective media overnight at 30ºC, they were subcultured into the same media at
21ºC or 37ºC for six hours and the fluorescence of the population was determined by flow
cytometry. As seen in Fig. 4, the expression of the pmrF operon is slightly higher at 21ºC than at
37ºC in both media conditions (p<0.05). In addition, there was significantly increased expression
of the pmrF operon in TB over M9 media at both temperatures.
We then wanted to determine if pmrF activity correlated with polymyxin resistance in Y.
pseudotuberculosis IP32953. We predicted that since we observed higher pmrF promoter
activity at 21ºC than 37ºC, we would also see higher resistance to polymyxin at this temperature.
We grew bacteria in TB media at either 21 or 37ºC and then exposed them to polymyxin for 2
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hours in a low-osmolarity buffer. As seen in Fig. 5, the survival of the bacteria grown at 37 ºC
was significantly higher than those grown at 21ºC, consistent with the pattern reported for strain
PB1. Therefore, resistance to polymyxin does not mirror promoter activity of pmrF.
When exposed to sublethal concentrations of antimicrobials, other bacteria increase
PhoP-PhoQ signaling and thereby upregulate L-Ara4N addition [92]. This may be a survival
mechanism where bacteria detect early signs of membrane disturbance and increase defensive
mechanisms. To investigate whether similar response could occur in Y. pseudotuberculosis, we
tested the effect of membrane-damaging antimicrobial substances that could be encountered
during infection on pmrF expression. These included the chemokine CCL28, CCL20, and human
serum. To test the effect of antimicrobial chemokines, the reporter strain was incubated with
CCL28 or CCL20 for 3-4 hours in TB at 37ºC and flow cytometry was used to measure pmrF
promoter activity. Incubating the bacteria in phosphate-buffered saline with either CCL28 or
CCL20 had no effect on pmrF expression (Fig. 6). To test the effect of normal human serum on
pmrF expression, bacteria were cultured in TB broth with 10% serum for 6 hours at both 21ºC
and 37 ºC. The presence of serum did result in a significant increase in promoter activity of the
operon (p < 0.05), but only at 21ºC (Fig. 7).
We reasoned that increased pmrF expression caused by serum in the growth media
should result in enhanced resistance to polymyxin. To test this, we pretreated the bacteria in the
same way as for the serum expression assay above. After the bacteria had incubated with or
without serum at 21ºC and 37ºC in TB media, they were washed and their ability to withstand a
polymyxin challenge was determined. Surprisingly, growth with serum at both temperatures
increased survival of polymyxin-challenged bacteria (Fig. 8) compared to bacteria grown without
serum. Therefore, increased expression of the pmrF operon when bacteria are exposed to human
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serum at 21ºC may enhance bacterial protection against polymyxin. However, since we saw a
similar increased resistance of bacteria grown in serum at 37ºC (despite no effect on pmrF
expression), other changes independent of pmrF may be caused by serum that result in increased
polymyxin resistance.
The ΔpmrI mutant of Yersinia pseudotuberculosis is more susceptible to killing by antimicrobial
chemokine CCL28
To investigate the role of the pmrF operon in resistance to antimicrobial peptides, we
created a ΔpmrI deletion mutant in the Y. pseudotuberculosis IP32953 strain. Since pmrF
expression was shown to vary with temperature, we wanted to determine whether ΔpmrI
mutation would affect resistance to polymyxin at 21ºC and 37 ºC. We tested the ability of wild
type and the ΔpmrI mutant to grow in the presence of varying concentrations of polymyxin. As
seen in Fig. 9, the mutant strain was significantly more sensitive to polymyxin at both growth
temperatures. Whereas the wild-type strain was uninhibited even at the highest levels of
polymyxin, the ΔpmrI mutant was no longer able to grow in polymyxin at the concentration of
1.5 µg/mL at 21ºC and 3.1µg/mL at 37ºC. This verified that the polymyxin resistance phenotype
was lost with knock-out of the gene. Interestingly we consistently saw slightly increased
resistance to polymyxin at 37ºC compared to 21ºC in the ΔpmrI mutant.
We then sought to determine the importance of the pmrF operon in Y. pseudotuberculosis
survival against antimicrobial chemokines. Bacterial defenses against antimicrobial chemokines
have not been thoroughly studied. However, since parallels have been made between
antimicrobial chemokines and cationic antimicrobial peptides [28-30], we predicted that LAra4N addition would be important in bacterial protection against these chemokines. We
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measured the survival of ΔpmrI mutant strain of Y. pseudotuberculosis when challenged with
CCL28 compared to those of the wild-type strain and to an hldD::Tn5 mutant, which has been
previously shown to be very sensitive to CCL28 killing [84, 85]. Survival was calculated by
dividing viable bacteria of the treated sample by viable bacteria in the BSA control. As shown in
Fig. 10, the ΔpmrI mutant strain had decreased survival compared to the wild-type, yet was able
to survive better than the hldD::Tn5 mutant. The difference between survival of the wild type
and pmrI knock-out strain was significant (p < 0.05).
CCL28 binding is reduced in the ΔpmrI mutant compared to wild type Y. pseudotuberculosis
In previous studies, it has been shown that Y. pseudotuberculosis mutations that increase
binding to CCL28 also result in reduced survival in the presence of the chemokine [84, 85]. To
determine if this relationship is also true for the ΔpmrI mutant, binding levels of CCL28 to wildtype, ΔpmrI, and ΔpmrI complemented strains of Y. pseudotuberculosis were measured using a
flow cytometry assay. While the wild-type and the complemented mutant had similarly high
levels of binding, surprisingly the ΔpmrI strain bound far less (p < 0.05) (Fig. 11).
Since these results conflict with previous studies using other mutants that have shown
killing correlates with binding, we wanted to investigate this result further. One possible
explanation is that the CCL28 is internalizing into the bacteria or falling off in solution. In an
attempt to determine if either of these situations are occurring, a binding assay with 5, 15, and 30
minute incubations with the chemokine was performed once. The results show that at each time
point the ΔpmrI mutant has lower binding levels compared to the wild type and pmrI
complement strains (data not shown).
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Neutrophils less efficiently phagocytize ΔpmrI mutant Y. pseudotuberculosis
Y. pseudotuberculosis depends on being able to resist the antimicrobial activities of
phagocytic cells, including neutrophils. While colonizing mucosal surfaces, high pmrF
expression levels and the presence of antimicrobial chemokines may influence the ability of
neutrophils to phagocytose the bacteria. To investigate these possibilities, a neutrophil
phagocytosis assay was developed wherein bacteria constitutively expressing GFP were
incubated with human neutrophils and flow cytometry was used to observe the percent of
neutrophils that had engulfed bacteria. The ΔpmrI strain of Y. pseudotuberculosis showed
decreased phagocytosis efficiencies compared to wild-type, even when opsonized with human
serum (p< 0.05) (Fig. 12). To determine if CCL28 binding has an effect on phagocytosis, wildtype Y. pseudotuberculosis constitutively expressing GFP was pretreated with either human
serum (positive opsonization control), CCL28, or BSA (negative control) and then incubated
with human neutrophils. Flow cytometry analysis revealed that the serum-opsonized bacteria
were better engulfed than non-opsonized bacteria. There was no change in neutrophil
phagocytosis ability when CCL28 was bound to the bacteria (Fig. 13).
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DISCUSSION
In these studies, we investigated how the bacterial environment influences expression of
the Y. pseudotuberculosis strain IP32953 pmrF operon, and how its activity influences bacterial
phenotypes relevant to virulence. We found that similar to other Yersinia species [53, 81], pmrF
expression in strain IP32953 at 37ºC is decreased as compared to 21ºC. However, it appears that
the media has a stronger influence on expression than growth temperature. There was a
significant decrease in expression when grown in M9 minimal media, compared to rich growth
media TB (Fig. 4).
The effects of nutrient availability may be relevant to the infectious strategy of Y.
pseudotuberculosis. Previous studies have used rich growth media when measuring pmrF
activity [53, 60], and we have determined here that nutrient availability may be a greater
influence on pmrF expression than temperature. As Y. pseudotuberculosis move through the
intestinal environment they would be exposed to high levels of nutrients, resulting in an increase
in pmrF expression. This could prepare them to resist antimicrobial peptides that are present in
the mucosal layer and are produced by epithelial cells when crossing the epithelial membrane.
After the bacteria cross the epithelial barrier and migrate through the lymph system they would
have decreased nutrient availability, possibly resulting in lower levels of pmrF expression.
According to our results in nutrient-reduced media, potentially reduced pmrF expression
beyond the intestinal mucosa could then increase survival against immune cells. The fact that
neutrophils were better able to phagocytose wild-type (pmrF expressing) bacteria than pmrI
mutants (Fig. 12) could indicate that downregulation of these genes might prevent clearance by
phagocytes. Further, others have shown that lipopolysaccharides from Burkholderia that have LAra4N induce stronger inflammatory responses than LPS without L-Ara4N [76, 77]. If the same
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is true for Y. pseudotuberculosis LPS then downregulation of the pmrF operon in this
environment might reduce cytokine production and activation of immune cells, thereby
promoting colonization in deeper tissues. To test this, pmrF transcript levels could be measured
using qPCR after Y. pseudotuberculosis mouse infection. It has previously been shown that LAra4N modified LPS can strongly activate the TLR4 complex on immune cells, even when lipid
A has a lower acylation pattern [77]. To test if the change in phagocytosis that is seen is purely a
TLR4 response to L-Ara4N modified bacteria, an anti-TLR4 antibody could be added to the
neutrophils to inhibit TLR4 activity before the bacteria are introduced. If the decrease in
phagocytosis was absent in the ΔpmrI strain, then it could be assumed that the decrease is due to
lower TLR4 activation on the neutrophils.
After determining that pmrF promoter activity was increased at 21ºC compared to 37 ºC,
we decided to test whether pmrF promotor activity correlated with polymyxin resistance. As
seen in Fig. 5, the survival of the bacteria grown at 37 ºC was significantly higher than those
grown at 21ºC, consistent with the pattern reported for strain PB1 [53]. Therefore, resistance to
polymyxin does not mirror promoter activity of pmrF. This may suggest that there are additional
regulatory mechanisms that act downstream of pmrF promoter activity that could modulate LAra4N addition, or that bacterial factors unrelated to the pmrF operon could influence survival in
polymyxin, especially at 37 ºC. The fact that a slight increase in resistance to polymyxin was
observed in the ΔpmrI mutant at 37ºC compared to 21ºC (Fig. 9) may indicate another
mechanism contributing to polymyxin resistance. To test this, we could create random
transposon mutants of the ΔpmrI mutant and perform the resazurin growth curve in various
levels of polymyxin to look for a mutant that results in no difference in survival against
polymyxin at either temperature.
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An important caveat of our results is that we measured expression only by pmrF reporter
expression. To verify these results, it will be necessary to further test pmrF expression by qPCR
transcriptional analysis of genes in this operon. Others have reported that transcripts of pmrF
virtually disappear at temperatures below 37ºC [60], but those studies used a different strain and
they did not show this data. If the qPCR analysis showed increased transcripts compared to
promoter activity, then we could assume that there is possibly another promoter site and alternate
regulator for the genes. However, if the transcript levels were comparative to that of the
promoter activity, then it’s possible that there is a downstream regulator possibly cleaving the
RNAs and preventing them from being translated. It would also be reasonable to assume that
there is another mechanism contributing to polymyxin resistance at 37ºC. Our finding that the
ΔpmrI mutant strain is hyper-susceptible to polymyxin both at 21ºC and at 37ºC strongly
suggests that L-Ara4N is added at both temperatures. Further, others have detected the presence
of L-Ara4N by mass spectrometry analysis of purified lipid A from Y. pseudotuberculosis at both
temperatures [60]. It is unknown the exact amount of L-Ara4N that is added at either
temperature. It will also be important to determine whether the PhoP-PhoQ system in Y.
pseudotuberculosis controls the temperature-dependent pmrF expression and polymyxin
resistance.
We decided to test pmrF expression in other conditions that Y. pseudotuberculosis might
encounter during infection that could cause membrane disruption, such as human serum and
antimicrobial chemokines. We found that in the presence of normal human serum there was an
increase in pmrF expression at 21ºC, but no significant effect at 37ºC (Fig. 7). Y.
pseudotuberculosis has the ability to resist killing by human serum at 37ºC due to expression of
YadA and Ail proteins at this temperature that prevent complement related killing [93]. Thus it is
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possible that complement activation does not progress sufficiently at 37ºC to activate similar
transcriptional changes seen at 21ºC. Clearly, it would be rare for Y. pseudotuberculosis to be
exposed to serum at lower temperatures. Thus the physiological relevance of the enhanced pmrF
expression in the presence of serum may be questioned. However, our results showing that
growth in serum at both 21ºC and 37ºC enhances bacterial survival on subsequent exposure to
polymyxin suggests an additional adaptive response independent of pmrF and L-Ara4N addition
that may contribute to resistance to host defense mechanisms (Fig. 8). In order to test if pmrF has
an effect on Y. pseudotuberculosis resistance against human serum, we could perform a normal
human serum killing assay with the wild-type and ΔpmrI strains of Y. pseudotuberculosis. To
test if the effects of the pmrF expression changes were due to complement binding, the same
expression assay could be repeated with heat killed serum. If there was still an increase in pmrF
expression, it could not be due to complement.
The addition of L-Ara4N in Y. pseudotuberculosis has benefits to the survival of the
bacteria when challenged against cationic antimicrobial peptides. This is well characterized in
several bacterial strains and the pmrF operon genes responsible for the addition of L-Ara4N have
appropriately been named for their effect on resistance to polymyxin (pmr stands for polymyxin
resistence). Antimicrobial chemokines can be constitutively produced by the intestinal lumen and
increased when bacteria invade. It is reasonable to assume that Y. pseudotuberculosis would
encounter CCL28 while entering a host. To determine the role that the pmrF operon plays in
bacterial protection against antimicrobial chemokines, two different antimicrobial chemokines,
CCL28 and CCL20 (a non-mucosal chemokine produced most highly in the lymph nodes, liver
and appendix [94]), were incubated with the bacteria for 3-4 hours and pmrF expression was
measured using flow cytometry. As seen in Fig. 6, there was no difference in pmrF expression
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when incubated with antimicrobial chemokine. This result is surprising, since when we tested
survival of the ΔpmrI mutant strain of Y. pseudotuberculosis against CCL28, we identified a
decreased survival rate compared to the wild-type (Fig. 10). However, survival of the bacteria,
while significant, is only marginally decreased, and other bacterial mutations have shown greater
reduction of survival [85]. It is possible that the addition of L-Ara4N is not one of the most
important methods to avoid killing by antimicrobial chemokines.
Previous research has shown that strains of Y. pseudotuberculosis that have high binding
to CCL28 also have low resistance to killing by CCL28 [84, 85]. Since we were seeing decreased
survival against CCL28 in the ΔpmrI mutant, we predicted that we would see increased binding
of the mutant compared to the wild-type bacteria. The levels of CCL28 binding to wild-type,
ΔpmrI, and ΔpmrI complemented strains of Y. pseudotuberculosis were not what we predicted.
As seen in Fig. 11, CCL28 appears to have high levels of binding to the wild-type and ΔpmrI
complemented strains, while the ΔpmrI strain had very low levels of binding. It is hard to say
what exactly is happening, but it is possible that the chemokine may be quickly internalizing into
the bacteria, or not stable enough on the surface of the bacteria to stay attached to the ΔpmrI
mutant. In an attempt to clarify the binding result, CCL28 levels on the surface were measured 5,
15, and 30 minutes after addition to the bacteria. If internalized, we expected to see high binding
of the ΔpmrI strain at the 5-minute mark, with increasingly lower binding at the other time
points. The ΔpmrI strain still had consistently lower binding than the wild-type and
complemented strains at every time point (data not shown). This would suggest that if the
chemokine is internalizing into the bacteria or falling off, then it is happening before we are able
to measure it using flow cytometry. It may be possible to detect internalized CCL28 by Western
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blot of bacterial lysates. It is also possible that the ΔpmrI mutation causes changes that interfere
with detection of bound CCL28.
One key difference in these experiments is that we used a virulent (pYV+) strain of Y.
pseudotuberculosis IP32953. CCL28 binding and killing patterns were previously determined in
a non-virulent strain of IP32953 [85]. Some preliminary data comparing the non-virulent and
virulent strains of IP32953 showed that CCL28 binding was very low in the pYV- strain and
high binding was seen in the pYV+ (data not shown). To follow up on this result, we created a
new pYV- strain from the pYV+ strain to see if the low binding phenotype would be observed,
and it was not. We chose to use the virulent strain for these experiments to maximize
applicability to strains able to cause human infection. CCL28 binding differences between
virulent and non-virulent strains of Y. pseudotuberculosis should be further explored.
Since the effects of CCL28 binding to the surface of bacteria have not been studied, we
wanted to know if there were any consequences to neutrophil phagocytosis when encountering a
bacterium that has been coated with CCL28. While it was hypothesized that binding of
antimicrobial chemokine to the surface of a bacterium would have an effect on neutrophil
phagocytosis, there appeared to be none (Fig. 13). It is possible that if the experiment were
modified to use a phagocyte that had receptors for CCL28, then perhaps the opsonization effect
would be seen. Eosinophils have chemokine receptor CCR10 that is one of the receptors for
CCL28 [33]. While neutrophils have not been shown to have CCR10, it has been seen in people
with chronic inflammatory diseases that neutrophils are able to produce the other CCL28
receptor, CCR3 [95].
Overall, these results indicate that additional investigation of polymyxin resistance
mechanisms in Y. pseudotuberculosis, as well as regulatory mechanisms for the pmrF operon in
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Yersinia species are warranted. They also suggest the intriguing possibility that while the pmrF
operon could be important for resistance against antimicrobial peptides, it may also increase
neutrophil phagocytosis (Fig. 14). This could help explain why previous research has shown no
effect of pmrF deletion on Y. pseudotuberculosis virulence in mice [60]. However, in a highly
virulent species like Y. pestis, removal of L-Ara4N at higher temperatures may be important for
escaping immune detection and phagocytosis. Thus, the regulatory differences in pmrF
expression that we observe may be adaptive and help explain the pathogenic differences between
these species.
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TABLES

Table 1. Primers used
Listed are all primers used for mutant and reporter generation.

pmrI upstream F

CTA CAG GGA AAT CAA TGG GTG ACT

pmrI upstream R

ACT CAT CTT TAG GGG CTG CAG TTT TCC CAC GCA ACC AAT
ATC ATG ATA GG

pmrI downstream F

TGC CTA TCA TGA TAT TGG TTG CGT GGC CCT AAA GAT GAG
TTG AAC GCA TG

pmrI downstream R

GTA CAC TCC CTA AGC TGC CAT TAG

pmrI nested F

GGC CGA TCT AGA GGT GAC TAC GGC TGC ATG CT

pmrI nested R

GCG ACG TCG ACC CTA AGC TGC CAT TAG GCA AC

pmrH pro F

GCG TGT CTA GAG GCG TTT AGT TTT CGT TAA CTT ATC
TGG GC

pmrH pro R

GCG CCG AAG CTT ACC TAT TGC TGG CCT AGA AAA AGG
CAA

Gfp F HindIII

GCG CCG AAG CTT ATG AGT AAA GGA GAA GAA CTT TTC
ACT G

Gfp R SalI

GCG AGC GTC GAC TTA TTT GTA TAG TTC ATC CAT GCC
ATG
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Figure 1. Lipid A modifications
The addition of L-Ara4N and acyl chain differences in the lipid A is shown here. These are modifications
made to Y. pestis as a model. The addition of L-Ara4N reduces the net-negative charge of the bacteria to
decrease detectability by cationic AMPs. Y. pseudotuberculosis has been shown to add L-Ara4N at both
temperatures, but follows the same trend for acylation pattern. Decreasing to a tetra-acylated pattern results in
lower immunostimulation, and increased chances of a successful infection.
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Figure 2. The role of individual genes in the addition of L-Ara4N
Figure 2a. The pmrHFIJKLM (pmrF) operon in Y. pseudotuberculosis is responsible for the production and
addition of L-ara4N to the lipid A.
Figure 2b. The functions that each gene in the pmrF operon carry out for the addition of L-ara4N. The pmrE
gene (not a part of the pmrF operon) produces the PmrE protein (Ugd) which transforms UDP-Glucose to UDPGlucuronic Acid. The C-terminal domain of PmrI (ArnA) causes the transition to UDP-ara4O. PmrH (ArnB)
makes a reversible change to UDP-L-ara4N. The N-terminal domain of PmrI can then add a formyl group to the
molecule and then PmrF (ArnC) transfers the molecule to the inner membrane by losing UDP and attaching to an
undecaprenyl phosphate. PmrJ (ArnD) removes the formyl group and then is transferred to the outer membrane
by an unknown function. PmrK (ArnT) is then able to transfer the L-ara4N onto the lipid A. It has been shown
that a loss of pmrL and pmrM does not prevent L-Ara4N addition (Yan 2007), but they are able to aid in the
transferring of L-Ara4N to the outer membrane. It is assumed that there are other genes that can supplement the
loss of pmrL and pmrM (Marceau 2009).
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Figure 3. PhoP-PhoQ regulatory mechanisms are compared between Y. psedotuberculosis, Y. pestis, and Salmonella
typhimurium
In Salmonella typhimurium, as well as Y. pestis, both the PhoP-PhoQ and the PmrA-PmrB regulatory
mechanisms are required for pmrF operon expression (A.). In Salmonella, when PhoP-PhoQ is activated by low
Mg2+ the pmrD gene is turned on and produces the PmrD protein which can activate the PmrA-PmrB regulatory
system, resulting in activation of the pmrF operon. PmrA-PmrB can also be activated by high Fe3+ levels. Y.
pestis lacks the pmrD gene and PmrA-PmrB activation is independent of PmrD (B).
In Y. pseudotuberculosis the regulation of the pmrF operon is independent of the PmrA-PmrB system and only
requires PhoP-PhoQ activation (C). Y. pseudotuberculosis does not have pmrD. It has been shown that ΔpmrApmrB mutants of Y. pseudotuberculosis do not have any pmrF defect. The same group has also shown that
pmrF expression can be regulated by a LysR-type regulator that increases expression in low Fe3+ conditions
(Marceau et al. 2004,2009).
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Figure 4. pmrF expression depends more on nutrient availability than temperature
A pmrF operon reporter strain of Y. pseudotuberculosis was incubated at 37°C and 21°C in either TB or M9
media. It is well known in other bacterial strains that pmrF expression is downregulated at 37°C, however it
appears that growth in rich media compared to minimal media is more important for expression. Differences in
expression are statistically significant between all test conditions (p > 0.05) and figure is representative of one
experiment done in triplicate. Experiment was performed with the same results three times.

*

Figure 5. Y. pseudotuberculosis is more resistant to polymyxin at 37ºC than 21ºC
Y. pseudotuberculosis was grown in TB media at either 21ºC or 37ºC and then exposed to polymyxin for 2 hours
in a low-osmolarity buffer. The survival of the bacteria grown at 37 ºC was significantly higher than those
grown at 21ºC (p > 0.05), consistent with previous studies.
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Figure 6. Antimicrobial chemokine presence does not affect pmrF expression
A pmrF operon reporter strain of Y. pseudotuberculosis was incubated at 37°C with and without the presence of
antimicrobial chemokines CCL28 and CCL20. There was no difference in pmrF expression between the negative
control and the addition of chemokine.
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*

Figure 7. Human serum increases pmrF expression at 21°C in TB
A pmrF operon reporter strain of Y. pseudotuberculosis was incubated at 37°C and 21°C in TB and M9 media
with and without being supplemented with 10% human serum. It is known that at 37°C, Y. pseudotuberculosis
is resistant to killing by human serum, and it appears that at this temperature serum has no effect on pmrF
expression. However, when incubated at 21°C, there appears to be an increase in expression when grown in
TB. Expression of pmrF at 37ºC is higher with serum than without (p > 0.05) and figure is representative of
one experiment done in triplicate. Experiment was performed with the same results three times.

*

*

Figure 8. Human serum helps protect Y. pseudotuberculosis from death by polymyxin
Y. pseudotuberculosis was pretreated in TB at 37°C and 21°C with and without 10% human serum for three
hours. A killing assay was then performed with polymyxin to see if the apparent increase in pmrF expression
would increase survival of the bacteria. The survival rate of the bacteria was significantly higher (p<0.05) when
pretreated with human serum at both 37°C and 21°C. Figure is representative of one experiment done in triplicate.
Experiment was performed with the same results three times.

42

Figure 9. The ΔpmrI mutant has decreased survival in polymyxin
To confirm that the created ΔpmrI mutant of Y. pseudotuberculosis had indeed lost the ability to survive in
polymyxin, and that pmrF expression related to polymyxin resistance, a growth curve was performed with
wild-type and ΔpmrI over 4.5 hours in varying levels of polymyxin at 21ºC and 37ºC. Growth was measured
by rezasurin metabolism. The wild-type bacteria were uninhibited by even the highest level of polymyxin
(left), while the ΔpmrI mutant was unable to grow in the higher concentrations (right). Suggesting that Lara4N is not being added in the ΔpmrI strain. This also shows that pmrF promoter activity does not
necessarily correlate with polymyxin resistance.
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Figure 10. Addition of L-ara4N helps protect Y. pseudotuberculosis against killing by antimicrobial chemokine
CCL28
The wild-type, ΔpmrI, ΔpmrI complement, and hldD::Tn5 strains of Y. pseudotuberculosis were incubated with
CCL28 in a low osmolarity media to determine how well they can survive against CCL28 killing. The wildtype and ΔpmrI + ppmrI strains were unaffected by CCL28, while the ΔpmrI strain had about a 30% decrease
in survival. HldD::Tn5 was used as a positive control for killing, with about a 50% survival rate. These results
show that L-ara4N addition is important as a bacterial defense against antimicrobial chemokines. The ΔpmrI
mutant has decreased survival compared to wild-type survival (p > 0.05) and figure is representative of one
experiment done in triplicate. Experiment was performed with the same results three times.
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*

Figure 11. The ΔpmrI mutant has decreased CCL28 binding
Wild-type, ΔpmrI, and ΔpmrI complemented strains of Y. pseudotuberculosis were incubated with CCL28 followed
by anti-CCL28 flurecently labeled antibody, to observe the amount of bacteria that were binding to CCL28. These
results show high binding for the wild-type and ΔpmrI + ppmrI strains of Y. pseudotuberculosis, with very low
binding to the ΔpmrI strain (p < 0.05). This conflicts what has been seen previously (Erickson 2016).
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Figure 12. L-ara4N addition increases neutrophil phagocytosis
The neutrophil phagocytosis assay was performed with fluorescent wild-type, ΔpmrI, and ΔpmrI complemented
strains. They were pretreated with or without serum opsonization. The results show that there is a decrease in
neutrophil phagocytosis when the pmrI gene is knocked out (p < 0.05). This is consistent with other recent
research that has been done showing that L-ara4N modified lipid A can be a greater stimulator of the innate
immune system. This can help to explain why the pmrF operon is down-regulated at 37°C. Figure is representative
of one experiment done in triplicate. Experiment was performed with the similar results three times.

Figure 13. CCL28 binding has no effect on neutrophil phagocytosis
Y. pseudotuberculosis containing the pAKgfp plasmid was pretreated with human serum (positive control),
BSA (negative control), and CCL28. The bacteria were then incubated with isolated human neutrophils for 30
minutes. The cells were then observed on a flow cytometer and the percent of neutrophils positive for GFP
were counted. The opsonized bacteria show a higher level of neutrophil engulfment. There was no difference
in engulfment from the negative control when the bacteria were bound to CCL28. These results suggest that
CCL28 does not act as a neutrophil opsonin.
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Figure 14. L-Ara4N addition most likely results in no change to net virulence
Although data suggests that the pmrF operon is be important for resistance against antimicrobial peptides, data
presented here suggests that it may also increase neutrophil phagocytosis. Combined these results help explain
why previous research has shown no effect of pmrF deletion on Y. pseudotuberculosis virulence in mice
(Marceau et al 2004).
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